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Abstract Nuclear localization has been observed for glycolytic
enzymes but not for key gluconeogenic enzymes. We report our
¢ndings on the intracellular localization of liver FBPase in rat
liver and kidney, the main organs in the endogenous glucose
production. Immuno£uorescence and confocal analysis revealed
that FBPase was present in the cytosol and, unexpectedly, inside
the nucleus of hepatocytes and proximal cells of the nephron.
Additionally, FBPase was found in the plasma membrane area
of adjacent hepatocytes where glycogen is synthesized and in the
apical region of proximal kidney cells. This subcellular distri-
bution in multiple compartments suggests the presence of di¡er-
ent localization signals on FBPase for diverse metabolic func-
tions.
( 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Synthesis of endogenous glucose occurs mainly in the liver
and kidney by gluconeogenesis from precursors such as glyc-
erol, amino acids, and lactate [1,2]. Fructose-1,6-bisphospha-
tase (FBPase, EC 3.1.3.11), a rate-limiting enzyme, catalyzes
the irreversible conversion of fructose-1,6-bisphosphate (Fru-
1,6-P2) to fructose-6-phosphate (F-6-P) and inorganic phos-
phate [3^5]. The existence of three FBPase isoenzymes: brain,
muscle and liver, has been proposed considering immunolog-
ical and kinetic data [3,6,7]. Although the rat muscle isoform
displays 70% identity with the hepatic form, the speci¢c phys-
iological role of the muscle and brain isoenzymes remains
unclear [8,9]. The liver FBPase isoenzyme is recognized to
be one of the major regulatory enzymes of gluconeogenesis
[1,2]. This isoenzyme, which has been isolated from di¡erent
organisms, is a tetramer composed of identical subunits (MW
36 000^41 000) and is mainly regulated by two synergistic in-
hibitors: AMP and fructose-2,6-bisphosphate (F-2,6-P2) [3^5].
We recently demonstrated, by using immunohistochemical
analysis in human tissues, that FBPase is expressed not only
in kidney and liver, but also in a variety of organs such as
small intestine, stomach, adrenal gland, testis and prostate,
which might also contribute to gluconeogenesis [10]. In hu-
man and rat kidney, the specialized distribution of liver
FBPase and cytosolic phosphoenolpyruvate carboxykinase
(PEPCK) only in the proximal convoluted tubules of the
nephron supports the idea that renal endogenous glucose pro-
duction occurs mainly in this region, whereas the distal tu-
bules speci¢cally contribute to the glycolytic activity [10,11].
Our results, showing aldolase B exclusively localized in the
proximal tubules in the cortex of rat kidney and preferentially
in hepatocytes of the periportal region of rat liver, are con-
sistent with this idea [12]. In rat and human liver FBPase is
expressed throughout the parenchyma in the hepatocytes.
Similarly to kidney, FBPase expression is compartmentalized
in rat liver with the periportal hepatocytes showing a higher
expression level with a gradient of concentration from this
region to the perivenous hepatocytes [10,11]. Additionally,
subcellular localization studies demonstrated that FBPase is
located in the perinuclear region of the positive staining cells
[10,11]. The presence of glycolytic enzymes inside the nuclei
has been reported [13^15]. However, due to the immunocyto-
chemistry technique used in the analysis we were unable to
distinguish between the nuclear and perinuclear location of
liver FBPase. In this study, we have taken advantage of the
immuno£uorescence and confocal analysis to show that the
liver FBPase is localized in a specialized plasma membrane
compartment and inside the nuclei in rat kidney and liver
cells, suggesting that the physical separation of metabolic
pathway within the cell is an interesting regulatory mecha-
nism.
2. Materials and methods
2.1. Antibody production. FBPase antibodies
FBPase was puri¢ed from pig kidney as described by Reyes et al.
[16]. Rabbit policlonal antiserum against pure FBPase was prepared
in white rabbits. Ten days after the booster injection the rabbits were
bled, and the presence of antibodies was checked by immunoblotting.
Rabbit serum immunoglobulins were prepared by ammonium sulfate
precipitation followed by DEAE^cellulose chromatography. This anti-
serum has a high speci¢city for the liver isoform and does not cross-
react with the muscle isoform [11].
2.2. Western blot
Sodium dodecylsulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) was performed using a minigel apparatus (Bio-Rad, Hercules,
CA, USA). The ¢nal acrylamide monomer concentration in the slab
gels was 10% (w/v) for the separating gel and 4% (w/v) for the stack-
ing gel. Extracted proteins from rat liver were electrophoretically
transferred from polyacrylamide gels to nitrocellulose membranes us-
ing a semi-dry Trans-Blot SD (Bio-Rad). The nitrocellulose-bound
protein was probed with the anti-FBPase sera, and the antibody-anti-
gen interaction was detected using secondary antibodies coupled to
peroxidase detection (Dako, Carpenteria, CA, USA).
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2.3. Immunohistochemistry
Liver and renal tissues obtained from fasted adult Holtzman rats
(body weight 300^350 g) were ¢xed in Bouin’s £uid, 4% (v/v) for 24 h
at room temperature. Fixed samples were dehydrated in ethanol and
embedded in paraplast plus (Monoject Scienti¢c, St. Louis, MO,
USA) or Hiscosec (Merck, Darmstadt, Germany). Immunostaining
was performed using the ‘Universal ICQ LSAB plus’ kit. The sections
were incubated with anti-FBPase antibodies (1:1000) washed and then
incubated with anti-rabbit IgG-biotin and the streptavidin/PAP com-
plex coupled to peroxidase detection. Control sections were incubated
with antibodies preabsorbed with FBPase or without the ¢rst anti-
body. The immuno£uorescence was performed using the same proce-
dure but replacing the secondary antibody with Alexa £uor 594 con-
jugated to goat anti-rabbit IgG (diluted 1/300) purchased from
Molecular Probes (Eugene, OR, USA). Controls were performed by
substituting the second antibodies by bu¡ers. The cross-reactivity of
the secondary antibodies was tested by substituting the target primary
antibody with normal serum or bu¡er. Stained sections were exam-
ined with a Zeiss (Thomwood, NY, USA) laser scanning confocal
microscope at the Centro de Estudios Cient|¤¢co, Valdivia (CECS).
The light source was argon/krypton laser and optical sections of
1 Wm were obtained.
3. Results
The immunoblot analysis demonstrated the presence of sim-
ilar immunoreactivity by liver FBPase in hepatic and renal
extracts. These results indicate that FBPase is present in a
similar amount in both tissues. Moreover, the analysis re-
vealed that the antibody detected two single bands with a
MW of 36 000 and 40 000, in kidney and liver extracts, respec-
tively (Fig. 1). The immunoreactive bands migrated at the
predicted subunit molecular weight, demonstrating the high
speci¢city of the prepared antibody. Minimal degradation of
these proteins was observed on both total tissue extracts. The
antibody does not react with other proteins and does not
recognize the muscle isoform (Fig. 1, lane 4).
Immunohistochemical detection of FBPase in kidney, using
the peroxidase reaction (DAB) and light microscopy, yielded a
strong signal at the proximal straight and convoluted tubules
located at the cortex but not in cells of the kidney medulla
(Fig. 2). The very low immunoreaction detected in the distal
convoluted tubules indicated low or non-existent expression of
FBPase (Fig. 2), with the distal cells providing an internal
control for the primary and secondary antibodies. At the sub-
cellular level, FBPase showed a strong reaction in the nuclei
of the proximal convoluted cells. The cytosol was also stained
and showed an apical localization of the enzyme. This unusual
organization of FBPase correlates with a subcellular compart-
mentalization of metabolic enzymes. FBPase exhibited a sim-
ilar immunoreaction level in the liver. This technique is unable
to quantify the amount of expressed enzymes; however, qual-
itative values show that FBPase is similarly expressed in prox-
imal tubule cells and periportal hepatocytes. FBPase immu-
nostaining was observed in the cytoplasm of the hepatocytes;
however, the periportal vein and endothelial cells were nega-
tive (Fig. 2). Particularly intense staining was seen in the
plasma membranes of adjacent cells (Figs. 2 and 4), suggest-
ing a special subcellular distribution of the FBPase, which
could be related to the glycogen synthesis. In addition, a
prominent perinuclear and nuclear staining was also observed
in hepatocytes from periportal regions. Immunostaining con-
trols replacing the primary antibody by non-immune rabbit
serum showed no immune reaction (data not shown).
The immunostaining pattern seen with conventional light
microcopy showed the association of FBPase to the nuclei
of rat liver and kidney cells. To identify the presence of
FBPase inside the nuclei, we performed immuno£uorescence
and confocal analysis taking optical sections of 1 Wm. The
results revealed a clear nuclear localization of FBPase in kid-
ney proximal tubule cells. The white arrow (Fig. 3) shows
several stained nuclei through the 1 Wm optical series, con-
¢rming this unexpected observation. Moreover, this analysis
demonstrated that FBPase is concentrated in the apical mem-
Fig. 1. Immunoblot with anti-liver FBPase. Lane 1, 2 Wg puri¢ed
pig kidney FBPase; lane 2, 20 Wg of rat liver homogenate; lane 3,
20 Wg of rat kidney homogenate; lane 4, 20 Wg of rat muscle ho-
mogenate.
Fig. 2. Localization of liver FBPase in kidney and liver by conventional light microscopy. Nuclear reaction (arrows). Scale bars, 10 WM.
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brane region. The nuclear localization of FBPase was detected
in several kidney samples; however, not all the cells of this
epithelium exhibited this staining. These results indicate that
not all the proximal tubule cells are in the same metabolic
state that allows the translocation of FBPase from the cytosol
to the nucleus. Similar results were observed in liver, con¢rm-
ing the relative abundance of this enzyme in the cytoplasm of
hepatocytes (Fig. 4A). The nuclear localization of FBPase in
these cells was also clearly observed (Fig. 4A). Additionally,
the nuclear staining was not uniform and the nucleolus was
negative for FBPase staining. Furthermore, the rotation of a
three-dimensional reconstruction of optical sections from he-
patocytes clearly shows that FBPase is concentrated at the
hepatocyte cell periphery forming uneven clumps, close to
the plasma membrane (Fig. 4B). No speci¢c staining was de-
tected in any of the negative controls without primary or sec-
ondary antibodies against rabbit IgG (data not shown).
4. Discussion
Glucose metabolic pathways are well de¢ned but the sub-
cellular organization of these pathways is poorly understood
in liver and kidney. Several factors a¡ect the net £ux of glu-
coneogenesis and allow the cells to respond to physiological
changes [1]. Ovadi and Srere have suggested that a new reg-
ulatory mechanism for metabolic pathways is the subcellular
compartmentalization and the physical separation of them in
a single cell [17,18]. These authors also underline the need for
a thorough characterization of the subcellular organization of
metabolic enzymes [17,18]. In this context, in muscle there is
convincing evidence about the interaction between some gly-
colytic enzymes and the subcellular cytoskeletal network, as-
sociation that regulates the location of glycolytic enzymes and
the kinetic rates of individual enzymes in the contraction pro-
cess [19^21]. In this report, we present the ¢rst data available
on the subcellular localization of liver FBPase in rat kidney
and liver cells that clearly describe the localization of FBPase
in the nucleus and in a compartment near the apical mem-
brane in kidney cells and in an area adjacent to the plasma
membrane in the hepatocytes.
Which are the physiological reasons for the localization of
FBPase in the periphery of these cells? Kidney contributes
with a signi¢cant fraction of the systemic gluconeogenesis
[22,23]. Recently, we have established that liver FBPase and
C-PEPCK are expressed mainly in the human proximal tubule
cells localized in the kidney cortex, indicating that the glucose
synthesis is compartmentalized to the proximal tubules
[10,11]. A similar distribution of glycolytic and gluconeogenic
enzymes has been described in kidney and liver [11,12,24,25],
suggesting that the separate localization of both pathways
within the nephron, coupled with the elevation of renal pre-
cursors in the proximal tubule, may represent an additional
physiological mechanism that stimulates the gluconeogenic
pathway and avoids the consumption of ATP by the forma-
Fig. 3. Immuno£uorescence of FBPase (red label) in kidney tissue. Proximal convoluted tubule optical sections of 1 Wm were obtained. Nuclei
(white arrows). Apical membrane (green arrows). Scale bars, 5 Wm.
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tion of futile cycles in a single cell [10,11]. Moreover, this
analysis suggests that the presence of these catalytically active
key enzymes is not su⁄cient to explain the mechanism respon-
sible for the variation in gluconeogenic rates from lactate in
the proximal tubules. Our ¢ndings [10], showing the expres-
sion of the monocarboxylated transporter 1 in the S1 segment,
may explain these di¡erent rates in the proximal tubule seg-
ments. The FBPase shows a specialized subcellular compart-
mentalization along rat kidney proximal tubules, being clearly
localized in the apical area of these cells. The treatment of a
kidney crude extract with Triton X-100 led to a signi¢cant
increase of 250% of the total activity of FBPase. From these
data we propose that FBPase may interact with transport
elements in the cellular membrane and play an important
function in the metabolic heterogeneity observed among the
proximal tubules. This functional duality of gluconeogenic
enzymes has been demonstrated for aldolase [26,27]. Indeed,
this enzyme plays a structural role in the polymerization of
actin and in the dynamic association of GLUT 4 vesicles with
actin, regulating glucose transport [26,27]. Also, we can pos-
tulate that glucose synthesis in these cells occurs in a subcel-
lular compartment adjacent to the apical membrane.
A similar metabolic zonation has been observed in rat liver,
demonstrating that hepatocytes from the periportal region of
rat liver mainly expressed the gluconeogenic enzymes, whereas
the hepatocytes located in the pericentral region mainly ex-
pressed glycolytic enzymes [11,24,28,29]. These data and other
interesting results strengthen the notion of the importance of
di¡erent metabolic functions for particular cells in bi-func-
tional organs [10,11,24,30]. The negative immunostaining in
non-hepatocyte cells is a good control for our antiserum and
supports the speci¢city of our subcellular localization. Inter-
estingly, FBPase was located at the periphery of the plasma
membrane of adjacent hepatocytes. Studies by Guinovart’s
laboratory have demonstrated that liver glycogen synthase
(GS) has a cytosolic distribution in the absence of glucose
and concentrates at the periphery of the hepatocyte when
the concentration of the hexose increases [31]. Additionally,
these authors showed that GS colocalizes with the glycogen
deposit stores in the membrane compartment, suggesting that
this enzyme remains attached to its product [32]. Glucose
depletion causes glycogen degradation and the redistribution
of the GS to the cytosol [33]. Our results show that the intra-
cellular distribution of FBPase closely resembles the GS and
Fig. 4. Immuno£uorescence of FBPase (red label) in liver tissue. A: Hepatocyte optical sections of 1 Wm were obtained. Nuclei (white arrow).
Plasma membrane (green arrows). Scale bars, 10 Wm. B: Rotation of a three-dimensional reconstruction of hepatocyte optical sections (1 Wm).
Scale bars, 5 Wm.
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glycogen localization and lead us to propose that FBPase in
this compartment is participating in the production of glucose
6-phosphate as a precursor for glycogen synthesis. Therefore,
the existence of this organized subcellular distribution and the
possible separation of glycogenogenesis and gluconeogenesis
pathways within a single cell might be the regulatory mecha-
nism that may explain how the kidney and hepatic cells can
segregate intermediates of competing metabolic pathways.
This idea is sustained by the capacity of the liver GS to di¡er-
entiate between glucose 6-phosphate produced by glucokinase
(GK) or hexokinase I and by the capacity of GS to use the
glucose 6-phosphate produced by gluconeogenesis from dihy-
droxyacetone [34]. Together these observations support the
proposal that the physical separation of FBPase in multiple
compartments and its interaction with enzymes that partici-
pate in glycogen synthesis and gluconeogenesis are required
for the regulation of these pathways.
Interestingly, the subcellular localization of FBPase in he-
patocytes and proximal tubule cells reveals that FBPase is also
able to translocate to the nucleus in these cell types. The
nuclear localization of muscle-FBPase was recently reported
[35]. This data corroborate our results on the ability of liver
FBPase to localize to the nuclei of liver and kidney cells.
Nevertheless, the authors discussed that rat liver FBPase
does not contain a nuclear localization sequence (NLS) com-
pared to the muscle isoform [35]. We agree that liver FBPase
does not contain this speci¢c canonical NLS, but the nature of
these signals is broad and liver FBPase may contain other
NLSs or a bipartite signal. Moreover, using neural networks
that predict subcellular location we found that liver FBPase
contains other classical NLSs (PXKRXKX) [36], that may
allow the translocation of FBPase into the nuclei.
Which are the physiological reasons for the localization of
FBPase inside the nuclei of kidney and liver cells? Broad
evidence exists about the nuclear translocation and cytosolic
redistribution of several enzymes in response to metabolic
conditions [13^15,37]. In the absence of glucose, GK is local-
ized in the nucleus of the hepatocytes, bound to its regulatory
protein, but moves into the cytoplasm when the levels of sugar
increase [15,38]. Muscular GS (M-GS) is also concentrated in
the nucleus at low glucose and at high glucose concentrations
translocates to the cytosol, where it adopts a particulate pat-
tern [37]. The nuclear role of GK in response to high glucose
concentration was proposed as a mechanism to minimize the
futile cycle between glucose and glucose 6-phosphate, an event
that represents an important mechanism for the regulation of
glucose metabolism [38]. We can also suggest a similar mech-
anism for the nuclear localization of FBPase in the cell avoid-
ing the formation of a futile cycle between F-6-P and Fru-1,6-
P2, as well as the degradation of FBPase. Moreover, it is
possible to postulate that other FBPase putative functions in
the nuclei might be the participation of the enzyme as tran-
scription factor, involvement in the phosphorylation/dephos-
phorylation process that regulates the activation of transcrip-
tion factors, or participation in the DNA metabolism. These
unusual ideas are supported by the demonstration that the
glycolytic enzymes lactate dehydrogenase and 3-phosphogly-
cerate kinase can reside in the nuclei of mammalian cells and
exert functions in DNA replication, transcription and DNA
repair, in addition to their role as catalysts in the cytoplasm
[13,14,39]. The transfer of these glycolytic enzymes to cell
nuclei requires phosphorylation [39] and notably rat liver
FBPase at the COOH terminus contains two AMP-dependent
phosphorylation sites [40]. The catalytic cytosolic function is
not altered by this modi¢cation; however, it can be respon-
sible for the FBPase nuclear localization and also for the
regulation of a new phosphatase function exerted by this en-
zyme in the nuclei.
On the other hand, it is also plausible to think that the
nuclear FBPase function is similar to the function of the cy-
tosolic form; participating in the glucose 6-phosphate produc-
tion. However, the amount of FBPase present in puri¢ed nu-
clei from liver and kidney tissues is lower than 2% of the total
activity present in the organs (data not shown), but the stain-
ing pattern indicates that FBPase concentration is high. These
two observations can be reconciled if we considerer the pos-
sibility that nuclear accumulation is a way to regulate the pool
of active/inactive enzyme. Finally, the binding ability of
FBPase to recognize several important metabolites can be a
regulatory linkage between the energy state of the cell and
nuclear functions.
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